As anti-PD-1/PD-L1 antibody drugs indirectly enhance T-cell reactivity and effector function, leading to the development of autoimmune diseases, PD-1/PD-L1 blockade therapies face many challenges in producing more beneficial clinical outcomes in patients. Here, CD274 is linked to autoimmune disease.